A focused review has highlighted TLR8-GOF as an “interface” disorder between bone-marrow failure and IEIs, and summarizes current therapeutic experience including antimicrobial prophylaxis, immunoglobulin replacement, immunosuppressive drugs and HSCT [173]. The gene discussed is TLR8; the disease is Bone marrow hypocellularity.